



## ASX ANNOUNCEMENT

### March 2024 Appendix 4C - Correction

**MELBOURNE, Australia (28 May 2024)** – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid point-of-care diagnostic technologies, provides a corrected Appendix 4C for the quarter ended 31 March 2024.

It has been brought to the Company’s attention that there was a clerical error in the Appendix 4C for the March 2024 quarter in the ASX announcement released on 23 April 2024. Specifically, the figure reported on line 8.4 erroneously includes the amount on line 8.1. A summary of the previously released and the corrected versions of Items 8.1 – 8.4 is highlighted below:

8.	Estimated cash available for future operating activities	\$US’000 Previous	\$US’000 Corrected
8.1	Net cash from / (used in) operating activities (item 1.9)	2,268	2,268
8.2	Cash and cash equivalents at quarter end (item 4.6)	3,366	3,366
8.3	Unused finance facilities available at quarter end (item 7.5)	2,606	2,606
8.4	Total available funding (item 8.2 + item 8.3)	8,240	5,972

Note that the responses to Items 8.5 and 8.6 are not impacted and remain the same.

-Ends-

***This announcement has been approved by the Lumos Disclosure Committee.***

#### About Lumos Diagnostics

*Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader*

For personal use only

platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).

### **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

### **Media Contacts:**

Haley Chartres – Australia

HACK Director

[haley@hck.digital](mailto:haley@hck.digital)

+61 423 139 163

### **Investor Contact:**

Jane Lowe

Managing Director, IR Department

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 411 117 774

### **Company Registered Office:**

Lumos Diagnostics Holdings Ltd

Level 4, 100 Albert Rd

South Melbourne, VIC 3205

[info@lumosdiagnostics.com](mailto:info@lumosdiagnostics.com)

+61 3 9087 1598

For personal use only

## Appendix 4C

### Quarterly Cash Flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Lumos Diagnostics Holding Limited

**ABN**

66 630 476 970

**Quarter ended ("current quarter")**

31 March 2024

<b>Consolidated statement of cash flows</b>	<b>Current quarter US\$'000</b>	<b>Year to date (9 months) US\$'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	6,684	9,122
1.2 Payments for		
(a) service delivery, research and development	(718)	(2,251)
(b) product manufacturing and operating costs	(908)	(2,505)
(c) advertising and marketing	(121)	(361)
(d) leased assets	-	-
(e) staff costs*	(1,570)	(3,915)
(f) administration and corporate costs	(1,029)	(2,717)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(70)	(419)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	471
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>2,268</b>	<b>(2,575)</b>

\*Staff costs have been allocated to their respective departments above.

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(13)	(22)
(d) investments	-	-
(e) intellectual property	-	-

Consolidated statement of cash flows	Current quarter US\$'000	Year to date (9 months) US\$'000
(f) other non-current assets (including capitalised product development costs)	-	(9)
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(13)</b>	<b>(31)</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	-	5,352
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	-	(353)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	(1,110)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other:		
Lease payments (principal component)	(243)	(922)
<b>3.10 Net cash from / (used in) financing activities</b>	<b>(243)</b>	<b>2,967</b>

Consolidated statement of cash flows		Current quarter US\$'000	Year to date (9 months) US\$'000
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	1,379	3,015
4.2	Net cash from / (used in) operating activities (item 1.9 above)	2,268	(2,575)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(13)	(31)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(243)	2,967
4.5	Effect of movement in exchange rates on cash held	(25)	(10)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>3,366</b>	<b>3,366</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter US\$'000	Previous quarter US\$'000
5.1	Bank balances	3,366	1,379
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>3,366</b>	<b>1,379</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	Current quarter US\$'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	292
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

<b>7. Financing facilities</b>	<b>Total facility amount at quarter end US\$'000</b>	<b>Amount drawn at quarter end US\$'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>		
<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1	-	-
7.2	-	-
7.3	2,606	-
7.4	2,606	-
7.5	<b>Unused financing facilities available at quarter end</b>	
		2,606
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	
	<p>The company put in place an A\$8.0m convertible note facility which was approved by shareholders at the general meeting on 22 December 2022. The facility is comprised of Tranche 1 of \$A4.0m and Tranche 2 of A\$4.0m (before costs).</p> <p>The company completed the draw down and settlement of Tranche 1 on 5 January 2023, with the balance owed subsequently repaid in full on 10 August 2023, with the cash amount for this loan repayment of \$1.1 million shown above in "cash flows from financing activities".</p> <p>The use of Tranche 2 for A\$4.0m (before costs) is subject to mutual agreement between the company and the two convertible note investors.</p> <p>Amounts shown above are for Tranche 2 based on an FX rate of A\$1.00 : US\$0.6516.</p>	

<b>8. Estimated cash available for future operating activities</b>	<b>US\$'000</b>
8.1	2,268
8.2	3,366
8.3	2,606
8.4	5,972
8.5	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?
	Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: The second payment of US\$5.0m under the IP Agreement with Hologic is due to be received by 30 June 2024.

The company is confident the second payment will be received in the timeframe outlined in the agreement.

It also should be noted that there are no costs related to the company's obligation under the IP agreement.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: This improvement in cash receipts from customers will provide a significant boost to operating cash flow, and funds available to the company.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **23 April 2024**

Authorised by: **The Lumos Disclosure Committee**  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.